Longeveron (NASDAQ:LGVN) Posts Quarterly Earnings Results, Misses Expectations By $0.21 EPS

Longeveron (NASDAQ:LGVN) released its earnings results on Thursday. The company reported ($1.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.70) by ($0.21), FiscalAI reports. Longeveron had a negative return on equity of 223.19% and a negative net margin of 1,977.59%. The firm had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.80 million.

Longeveron Stock Performance

Shares of Longeveron stock traded down $0.33 on Thursday, reaching $2.97. 77,408 shares of the stock were exchanged, compared to its average volume of 207,192. The firm’s 50 day moving average is $3.08 and its 200-day moving average is $6.47. The firm has a market cap of $9.47 million, a PE ratio of -0.30 and a beta of -0.09. Longeveron has a one year low of $1.31 and a one year high of $12.30.

Analyst Ratings Changes

Several analysts recently issued reports on LGVN shares. Weiss Ratings lowered Longeveron from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, September 8th. Wall Street Zen raised shares of Longeveron from a “sell” rating to a “hold” rating in a report on Saturday, October 31st. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $80.00.

About Longeveron

Longeveron Inc. is a clinical-stage biotechnology company focused on developing regenerative medicines for serious and life-threatening conditions. The company’s research centers on cell-based therapies intended to support tissue repair, reduce harmful inflammation and promote the body’s natural healing processes. Longeveron’s lead investigational product is Lomecel-B, an allogeneic cell therapy derived from bone marrow obtained from healthy adult donors. The company has evaluated Lomecel-B in clinical programs addressing hypoplastic left heart syndrome, a rare congenital heart defect in infants, as well as Alzheimer’s disease and aging-related frailty.